Kadcyla received an FDA nod for adjutant treatment of HER-2 positive breast cancer, hopefully offsetting declining sales of Roche's Herceptin. (Roche) As its onc...

Gilead's most advanced drug for non-alcoholic steatohepatitis, a fatty liver disease better known as NASH, has failed a second late-stage clinical trial, arguably co...

Drugmakers are taking longer to move a medicine from initial human testing to approval, with cumulative development times increasing from an average of about 10 year...

Roche's Tecentriq nabbed key approvals in breast cancer and small-cell lung cancer last month.  Roche’s Tecentriq has scored some important victories lately, inc...

A Pfizer vaccine candidate meant to protect against 20 different strains of pneumococcal disease was well-tolerated, safe and elicited an immune response in a Phase ...